Cargando…

A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis

Globally, an estimated 131 million new cases of chlamydial infection occur annually. Chlamydia trachomatis infection can cause permanent damage to the fallopian tubes in woman, resulting in infertility and a risk of ectopic pregnancy. There is a great need for a vaccine against Chlamydia trachomatis...

Descripción completa

Detalles Bibliográficos
Autores principales: Grasse, Marco, Rosenkrands, Ida, Olsen, Anja, Follmann, Frank, Dietrich, Jes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033180/
https://www.ncbi.nlm.nih.gov/pubmed/29513398
http://dx.doi.org/10.1002/cyto.a.23353
_version_ 1783337654481321984
author Grasse, Marco
Rosenkrands, Ida
Olsen, Anja
Follmann, Frank
Dietrich, Jes
author_facet Grasse, Marco
Rosenkrands, Ida
Olsen, Anja
Follmann, Frank
Dietrich, Jes
author_sort Grasse, Marco
collection PubMed
description Globally, an estimated 131 million new cases of chlamydial infection occur annually. Chlamydia trachomatis infection can cause permanent damage to the fallopian tubes in woman, resulting in infertility and a risk of ectopic pregnancy. There is a great need for a vaccine against Chlamydia trachomatis and as a result there is a need for assays to evaluate functional immune responses for use in future clinical trials and epidemiological studies. Antibodies play a crucial role in the defense against infection and can be protective by several functions, including phagocytosis and neutralization. Vaccine development could greatly benefit from a method to measure functional C. trachomatis‐specific antibodies in a large number of samples. In the current in vitro antibody protection assays, which measure the capacity of antibodies to facilitate phagocytic uptake of C. trachomatis, the phagocytosed bacteria have to be counted manually. This is both labor demanding, time consuming, and it prevents high‐throughput usage of this method. In this study, we, therefore, developed a simple and rapid flow cytometry based assay to measure the capacity of antibodies to mediate Fc‐receptor dependent phagocytosis. This method is highly reproducible and suitable to analyze large numbers of clinical and nonclinical samples. © 2018 The Authors. Cytometry Part A Published by Wiley Periodicals, Inc. on behalf of ISAC.
format Online
Article
Text
id pubmed-6033180
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60331802018-07-12 A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis Grasse, Marco Rosenkrands, Ida Olsen, Anja Follmann, Frank Dietrich, Jes Cytometry A Original Articles Globally, an estimated 131 million new cases of chlamydial infection occur annually. Chlamydia trachomatis infection can cause permanent damage to the fallopian tubes in woman, resulting in infertility and a risk of ectopic pregnancy. There is a great need for a vaccine against Chlamydia trachomatis and as a result there is a need for assays to evaluate functional immune responses for use in future clinical trials and epidemiological studies. Antibodies play a crucial role in the defense against infection and can be protective by several functions, including phagocytosis and neutralization. Vaccine development could greatly benefit from a method to measure functional C. trachomatis‐specific antibodies in a large number of samples. In the current in vitro antibody protection assays, which measure the capacity of antibodies to facilitate phagocytic uptake of C. trachomatis, the phagocytosed bacteria have to be counted manually. This is both labor demanding, time consuming, and it prevents high‐throughput usage of this method. In this study, we, therefore, developed a simple and rapid flow cytometry based assay to measure the capacity of antibodies to mediate Fc‐receptor dependent phagocytosis. This method is highly reproducible and suitable to analyze large numbers of clinical and nonclinical samples. © 2018 The Authors. Cytometry Part A Published by Wiley Periodicals, Inc. on behalf of ISAC. John Wiley and Sons Inc. 2018-03-07 2018-05 /pmc/articles/PMC6033180/ /pubmed/29513398 http://dx.doi.org/10.1002/cyto.a.23353 Text en © 2018 The Authors. Cytometry Part A Published by Wiley Periodicals, Inc. on behalf of ISAC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Grasse, Marco
Rosenkrands, Ida
Olsen, Anja
Follmann, Frank
Dietrich, Jes
A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis
title A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis
title_full A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis
title_fullStr A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis
title_full_unstemmed A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis
title_short A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis
title_sort flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against chlamydia trachomatis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033180/
https://www.ncbi.nlm.nih.gov/pubmed/29513398
http://dx.doi.org/10.1002/cyto.a.23353
work_keys_str_mv AT grassemarco aflowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT rosenkrandsida aflowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT olsenanja aflowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT follmannfrank aflowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT dietrichjes aflowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT grassemarco flowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT rosenkrandsida flowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT olsenanja flowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT follmannfrank flowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis
AT dietrichjes flowcytometrybasedassaytodeterminethephagocyticactivityofbothclinicalandnonclinicalantibodysamplesagainstchlamydiatrachomatis